The U.S. Food and Drug Administration granted a priority review for GlaxoSmithKline plc’s Biologics License Application seeking approval of belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc. and Biogen Inc. hiked U.S. list prices on more than 50 drugs to begin 2020, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by 3 Axis Advisors.
ASH Roundup: Bristol-Myers Squibb, bluebird bio, Oryzon and More
Acute Myeloid Leukemia (AML), American Society of Hematology (ASH) Annual Meeting, Chronic Lymphocytic Leukemia (CLL), Clinical Data, Clinical Trials, Diffuse Large B-Cell Lymphoma (DLBCL), Epigenetic, LSD1, Myelodysplastic Syndromes, Progression-Free Survival (PFS), R&D, Relapse/Refractory Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Small MoleculesHundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
Bluebird bio Inc. and Bristol-Myers Squibb Co. reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 ALCYONE study showing the addition of Darzalex to bortezomib, melphalan and prednisone (D-VMP) improved overall survival (OS) in patients with newly diagnosed, transplant-ineligible multiple myeloma, with a 40 percent reduction in the risk of death compared to VMP alone.
The European Commission granted marketing authorization for Janssen’s Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant.
Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.
Amphivena Therapeutics Inc., a private clinical stage immuno-oncology company developing T-cell engager therapeutics for cancer, announced the closing of a $62 million Series C financing.
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
